Illumina, Inc.


SKU: ILMN-1 Category:


Illumina managed to surpass the revenue expectations as well as the earnings expectations of Wall Street. In Q1, Illumina produced revenue of about $1.09 billion. The company’s goal for the rest of the year is to provide sequential growth primarily through scaling the manufacturing and distribution of NovaSeq X, thereby increasing elasticity and boosting margins. During the first quarter, they shipped the first NovaSeq X systems. Illumina’s competitive position in high-throughput sequencing was further enhanced by the launch of NovaSeq X. The company ended the first quarter with more than 200 orders received from more than 30 countries, reflecting the continued strong global demand for the NovaSeq X Series. About 40% of orders were for clinical products, which continues to outperform expectations. Illumina also unveiled Illumina Complete Long-Read technology and Illumina Connected Insights. Furthermore, the company announced the expansion of its collaboration with Myriad Genetics in March in order to increase access to testing for HRD. Additionally, in oncology, GRAIL experienced growing demand for its Galleri multi-cancer early detection blood test, and it produced revenue of $20 million. The company further collaborated with the African Centre of Excellence for Genomics of Infectious Diseases to create a training academy. The partnership aims to boost Africa’s genomics capabilities. We give Illumina, Inc. a ‘Hold’ rating with a revised target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!